- Open Access
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance
Orphanet Journal of Rare Diseases volume 14, Article number: 118 (2019)
Mucopolysaccharidosis (MPS) VI or Maroteaux-Lamy syndrome (253200) is an autosomal recessive lysosomal storage disorder caused by deficiency in N-acetylgalactosamine-4-sulfatase (arylsulfatase B). The heterogeneity and progressive nature of MPS VI necessitates a multidisciplinary team approach and there is a need for robust guidance to achieve optimal management. This programme was convened to develop evidence-based, expert-agreed recommendations for the general principles of management, routine monitoring requirements and the use of medical and surgical interventions in patients with MPS VI.
26 international healthcare professionals from various disciplines, all with expertise in managing MPS VI, and three patient advocates formed the Steering Committee group (SC) and contributed to the development of this guidance. Members from six Patient Advocacy Groups (PAGs) acted as advisors and attended interviews to ensure representation of the patient perspective. A modified-Delphi methodology was used to demonstrate consensus among a wider group of healthcare professionals with expertise and experience managing patients with MPS VI and the manuscript has been evaluated against the validated Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument by three independent reviewers.
A total of 93 guidance statements were developed covering five domains: (1) general management principles; (2) recommended routine monitoring and assessments; (3) enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT); (4) interventions to support respiratory and sleep disorders; (5) anaesthetics and surgical interventions. Consensus was reached on all statements after two rounds of voting. The greatest challenges faced by patients as relayed by consultation with PAGs were deficits in endurance, dexterity, hearing, vision and respiratory function. The overall guideline AGREE II assessment score obtained for the development of the guidance was 5.3/7 (where 1 represents the lowest quality and 7 represents the highest quality of guidance).
This manuscript provides evidence- and consensus-based recommendations for the management of patients with MPS VI and is for use by healthcare professionals that manage the holistic care of patients with the intention to improve clinical- and patient-reported outcomes and enhance patient quality of life. It is recognised that the guidance provided represents a point in time and further research is required to address current knowledge and evidence gaps.
Mucopolysaccharidoses (MPS) are part of a clinically heterogeneous group of diseases known as lysosomal storage disorders (LSDs), of which there are over 60 different types. Symptoms of MPS occur because of deficiencies in enzymes that break down glycosaminoglycans (GAGs) [1,2,3]. Eleven different enzymes are responsible for the stepwise degradation of GAGs, deficiencies in each of which are responsible for seven different types of MPS . Patients with MPS typically seem healthy at birth, but symptoms usually appear during early childhood as the concentration of GAGs in cells increases. The pursuant effect on tissues and organs cause severe morbidity and reduced life expectancy [5, 6]. Clinical features can vary according to MPS subtype, but coarse features, organomegaly, skeletal and joint abnormalities, dysfunction in vision and hearing and cardiorespiratory problems are common across all MPS subtypes .
MPS VI or Maroteaux-Lamy syndrome (253200) is an autosomal recessive MPS disorder caused by deficiency in N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ASB; EC 126.96.36.199). Birth prevalence has been reported to range from 1 in 43,261 live births in Turkish immigrants living in Germany  to 1 in 1,505,160 live births in Sweden [8, 9]. ASB catalyses the breakdown of dermatan sulphate, which is present particularly in the skin, but is also found in tendons, blood vessels, airways and heart valves . Preclinical data have shown that dermatan sulphate effects an inflammatory response via the tumour necrosis factor (TNF) pathway, and its accumulation results in apoptosis of chondrocytes and ensuing progressive arthropathy [11, 12].
MPS VI is classified according to severity of symptoms and is typically termed as being either slowly or rapidly progressing; however, it is now known that an intermediate form between slowly and rapidly progressing MPS also exists. Presentation differs according to age of onset and velocity of disease progression; and higher urinary GAG levels are associated with rapidly progressing disease . However, a large number of mutations of the ASB gene have been identified and are believed to be responsible for the heterogeneity in presentation . Although elevated urinary GAGs and increased dermatan sulphate concentrations are markers of the disease, these alone do not provide a definitive diagnosis. Diagnosis is generally accepted by confirmation in an accredited laboratory of ASB enzyme activity in cultured fibroblasts or isolated leukocytes of < 10% of the lower limit of normal and/or demonstration of two disease-causing mutations [9, 14, 15]. Symptoms of MPS VI include decreased growth velocity, coarse facial features, skeletal deformities, frequent upper-airway infections, enlarged liver and spleen, hearing loss, joint stiffness and coarse hair . Abnormalities of cardiac valve anatomy and function are present in all patients with MPS VI  and are attributed to the deposition of dermatan sulphate within the cardiac valves.
MPS are rare diseases; therefore, the small patient population of patients with MPS VI precludes the generation of large datasets through participation in Phase 3 trials, and consequently the availability of top-level evidence through meta-analyses. Although guidance for MPS VI has been published , owing to the lack of available evidence, the provision of credible guidelines in rare diseases requires the use of robust methodology to provide expert-driven, consensus-based guidance. The guidance provided in this manuscript represents a transition from expert opinion in prior documents to a validated approach that includes a comprehensive literature review and a modified Delphi process.
The scope of the programme was to develop guidance for the management of two MPS without neurocognitive manifestations, namely MPS IVA and MPS VI. This manuscript provides robust evidence- and consensus-based guidance for the management of adult and paediatric patients with MPS VI. The guidance is comprised of a holistic set of recommendations for the timely and appropriate use of medical and surgical interventions and management of the natural history of MPS, with the intention to maintain and enhance patient quality of life and improve clinical- and patient reported- outcomes. The guidance is intended for use by healthcare professionals who manage the care of patients with MPS VI, in particular paediatricians and geneticists, and aims to enhance multidisciplinary practice across specialisms. It also provides specific guidance for other specialists (Table 1) and stakeholders in the health services who are in contact with patients with MPS and is a useful reference for patient advocates, patients and their families. Table 1 describes the areas of clinical focus covered within this guidance and the corresponding recommended speciality focus.
This guidance was developed as part of a broader consensus programme that also covered the management of MPS IVA, the results of which are published in a companion article ( Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance ).
Methods and process
As the methodology for guidance pertaining to both MPS IVA and MPS VI consensus was conducted in parallel, the full methodology is reported in a companion article: Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance .
Briefly, the methodology included: a systematic expert mapping process to identify the programme Co-Chairs; recommendations from the Co-Chairs to align the international Steering Committee (SC) group; numerous face-face and online SC meetings to define the clinical questions to be answered by the guidance according to the P.I.C.O methodology (Additional file 1: Appendix 1a); a systematic literature review to identify the evidence base for each clinical question in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Additional file 1 Appendices 1b and 1c) ; assessment of the quality of evidence level for each paper using the Oxford Centre for Evidence-based Medicine criteria (Additional file 1: Appendix 2 and Additional files 2 and 3); consultations with six global Patient Advocate Groups (PAGs) [listed in the acknowledgements section of the manuscript] to generate insights to inform the development of guidance statements; drafting of guidance statements by the SC via a series of face-to-face, online meetings and email correspondence; validation of the guidance statements by a modified-Delphi survey [18, 19] (the full results including the number of voters/statement, respondent specialisms and geographies, and respondent feedback to guidance statements are included within Additional files 4 and 5); grading of recommendation statements based on the average evidence level for each supporting reference (Additional file 1: Appendix 2 and Additional files 2 and 3) and independent assessment of the manuscript by three reviewers using the Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument  (full information including the scores from the two rounds of AGREE II evaluation can be found in Additional file 1: Appendix 3).
The SC consisted of four Co-Chairs and a further 22 healthcare professionals were convened from a wide geographic spread covering multiple medical specialties including: anaesthesia, ear, nose and throat (ENT) surgery, cardiology, endocrinology, genetics, hand surgery, haematopoietic stem cell transplantation (HSCT), neurosurgery, ophthalmology, orthopaedic surgery, paediatrics, pain management and pulmonology. To ensure the patient view was considered, three representatives from PAGs also formed part of the SC group. The SC defined the scope of the programme, identified the medical and surgical interventions to be covered in the guidance and provided search terms for the literature review. More information about the SC, including their details, competing interests and contributions can be found in the declarations section of the manuscript.
Setting the clinical questions to be answered by the guidance
The SC group developed the clinical questions to be answered by the guidance according to the patient, interventions, comparator and outcome (P.I.C.O.) methodology (outlined in Additional file 1: Appendix 1a) and are shown below.
What are the general principles for the management of adult and paediatric MPS VI?
What are the recommended routine monitoring and assessments that should be used to track the natural history of adult and paediatric MPS VI and indicated interventions to be used in the management of the common symptoms of MPS VI?
For patients with adult and paediatric MPS VI, what is the impact on clinical outcomes and safety/tolerability of:
Interventions that address the underlying enzyme deficiency
Interventions used to manage the symptoms of MPS
◦ Respiratory and sleep disorders
◦ Limb and spinal surgeries
◦ Ophthalmic surgeries
◦ Cardio-thoracic surgeries
◦ ENT surgeries
The programme also had a secondary focus to highlight current evidence gaps and provide recommendations for future treatment directions. This programme did not cover the following topics: diagnosis, validation of new clinical outcome assessment tools (e.g. to assess patient-reported outcomes) and defining minimal clinically important differences for MPS IVA/VI.
Measures to address independence
The programme was funded by BioMarin; however, they remained uninvolved throughout the whole process and did not influence the scope or content of the programme. The funder was absent from all SC meetings, remained blinded to the guidance statements and was not involved in the publication process. An independent secretariat (Lucid Partners Ltd) managed the programme and provided editorial support. The SC led the scope and content of the programme, including the development of guidance statements. Conflicts of interests for all SC members (found in the declarations section) were recorded at the start of the programme and updated throughout the programme. Following the systematic expert mapping exercise, it was noted that some of the SC had previously worked on a consultancy basis with the programme sponsor, who hold the marketing authorisation for approved pharmaceutical therapy in MPS VI. Efforts were therefore taken to ensure representation from leading experts across other treatment modalities, including HSCT/BMT on the Steering Committee panel and during the modified-Delphi voting process, where a large number of physicians across multiple specialisms and geographies were engaged. At several stages during the process, the SC were also required to provide updated conflict of interest disclosures.
The results of the modified-Delphi voting process are described in more detail in the companion publication ( Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance ).
After two rounds of anonymised voting via an online survey (from a pool of 197 MPS physicians across 35 clinical areas of focus in 25 countries worldwide), consensus was reached on 94 validated guidance statements pertaining to the management of patients with MPS VI (further information about the modified-Delphi process, including: the number of voters/statement, respondent specialisms and geographies, and respondent feedback to guidance statements are shown in Additional files 4 and 5).
Three independent reviewers (listed in the acknowledgements section of the manuscript) assessed the guidance for methodological rigour and transparency against the validated Appraisal of guidelines for research and evaluation (AGREE II) instrument. The guidance documents were given an overall guideline assessment score of 5.3/7 (where 1 represents the lowest quality, and 7 represents the highest quality). Full information including the assessment scores across each domain criteria are outlined in Additional file 1: Appendix 3.
General principles (Table 2)
The diagnosis of MPS VI was deemed out of scope for this guidance, but details can be found elsewhere [14, 15]. The SC noted that if newborn screening is made available, this would facilitate earlier diagnosis and intervention for patients with MPS VI, which is likely to change the course of their disease. As the most serious surgical complications occur in patients with advanced MPS, surgical procedures (particularly airway procedures) where indicated, should be conducted as soon as possible. Guidelines for pain management in patients with MPS have recently been published [21, 22].
Recommended routine monitoring and assessments (Table 3)
ERT (galsulfase) in patients with MPS VI (Table 4)
Rationale and evidence base Galsulfase is a recombinant form of human lysosomal enzyme N-acetylgalactosamine 4-sulfatase, an enzyme that is deficient in patients with MPS VI. Treatment with galsulfase aims to transiently restore N-acetylgalactosamine 4-sulfatase activity, thereby preventing the accumulation of GAGs in lysosomal compartments of cells, which causes the clinical manifestations of MPS VI . It is currently the only disease-specific treatment for MPS VI that is licensed and has been validated in clinical trials and long-term post-marketing surveillance studies [41,42,43,44]. Administration in patients with high baseline urinary GAG levels resulted in a statistically significant increase in height Z-score from pre-treatment baseline to last follow-up for those beginning treatment at 0–3, > 3–6, > 6–9, > 9–12, and > 12–15 years of age . Galsulfase has been shown to improve endurance (as measured by the 6 min walk test [MWT], 12MWT and 3-min stair climb [3MSC]) [25, 40, 41, 45,46,47,48,49] and pulmonary function (as measured by increases in forced vital capacity [FVC] and forced expiratory volume [FEV1]), which may, in part, be attributed to growth in young patients . Results suggest that if initiated early (in patients under 16 years of age), galsulfase also results in an improvement in growth velocity, although comparative data in patients who have not received ERT are limited [41,42,43,44]. When initiated early (in patients under 12 years of age), long-term treatment with ERT is effective in preventing the progression of cardiac valve abnormalities; however, the resultant effect on cardiac outcomes is equivocal [50, 51]. There is a trend for improvement in spleen and liver size [42, 52,53,54], facial dysmorphia , joint mobility and decreased pain [40, 52, 53, 55], and findings are suggestive of slowing of bone disease progression .
The most common adverse events reported in the galsulfase clinical studies include pyrexia, rash, pruritus, urticaria, chills/rigors, nausea, headache, abdominal pain, vomiting and dypsnoea. Serious adverse reactions included laryngeal edema, apnoea, pyrexia, urticaria, respiratory distress, angioedema, asthma and anaphylactoid reaction. Infusion-associated reactions (IARs), defined as adverse reactions occurring during galsulfase infusions or until the end of the infusion day, were observed in 33 (56%) of the 59 patients treated with galsulfase across five clinical studies [57, 58].
The safety and superior efficacy of galsulfase when administered from a young age has been demonstrated in several sibling-controlled studies [59,60,61]. However, most available data are from patients who initiate ERT later in the course of disease and additional studies are warranted to determine the long-term outcomes of galsulfase treatment when administered from an early age.
Considerations prior to starting ERT Patient status, disease burden and ultimate prognosis at the time of diagnosis must be accounted for when deciding the timing for initiation of ERT. Initial administration of galsulfase should be performed (where possible) by a clinician with experience of metabolic disorders and in an infusion centre or hospital with the necessary facilities to effectively manage IARs/anaphylactic reactions, should this be required. Home infusion may be considered in regions where this is available; this decision should be made by both the physician and patient. Careful patient selection, good vascular access and a detailed management plan for IARs/anaphylaxis are essential for the success of this approach. Consideration should be given to the need for a totally implantable vascular access device (TIVAD) to facilitate long-term venous access for frequent or continuous administration of ERT. Patients and their families should be made aware of the benefits and risks of using such a device as outlined in two case series [62, 63].
Considerations for monitoring response Baseline and follow-up assessments to measure treatment efficacy should be performed prior to and regularly after initiation of galsulfase. These should include GAG/dermatan sulphate concentration, endurance testing, upper limb function, respiratory function (if age-compatible), growth, height and weight, pain, activities of daily living (ADL) and quality of life (QoL). It is important to assess the life-long impact of galsulfase on an individual basis, as the benefits of treatment may not be consistent across all patients [43, 64].
Considerations for managing specific adverse events Due to the potential for hypersensitivity reactions with galsulfase, patients who were treated with galsulfase in the clinical trial programmes received antihistamine premedication, with or without antipyretics, 30–60 min prior to the start of the infusion. Owing to concerns about the risk of hypersensitivity reactions with galsulfase, this approach is broadly followed in clinical practice; however, there is limited evidence in support of the necessity of premedication use. Patients should be closely observed for signs of anaphylaxis during and after administration of galsulfase and if suspected, hospital admission is advised. IARs are generally manageable by reducing the rate of administration or by temporary interruption of the infusion and the administration of additional antihistamines and antipyretics. Due to the risk of sleep apnoea in patients with MPS VI, use of a non-sedating antihistamine is recommended.
HSCT in patients with MPS VI (Table 5)
Rationale and evidence base The strongest data supporting the role of HSCT as a treatment for MPS is derived from subtypes other than VI; specifically, MPS IH (Hurler disease) [65, 66]. HSCT is currently the standard of care in patients with MPS IH because of its associated improvement in central nervous system (CNS) disease, which is not effectively treated by ERT [66,67,68,69,70]. The incidence of hydrocephalus and cervical stenosis in patients with MPS IH is reported to be lower in those treated with HSCT versus ERT ; however, as cognitive deficits similar to those seen in patients with MPS IH have not been observed in patients with MPS VI, it is unclear whether HSCT would be an effective treatment for MPS VI.
Evidence supporting the use of HSCT in patients with MPS VI is currently lacking, being based on a small number of case studies and results from non-randomised follow-up studies [72,73,74,75,76]. Evidence from case studies in patients with MPS VI suggests that HSCT increases the enzymatic activity of N-acetylgalactosamine 4-sulfatase in circulating white blood cells, and has a positive effect on joint mobility, ENT and cardiac manifestations, movement, QoL, as well as reducing facial dysmorphism . Normalisation of urinary GAG and dermatan sulphate levels and slowed disease progression have been observed in patients with mild MPS VI phenotypes, with variable outcomes observed in visual acuity [77, 78]. There are limited survival data post-HSCT in patients with MPS VI. Although now somewhat dated, results of a retrospective study of HSCT outcomes in patients with MPS VI (for transplants performed between 1982 and 2007) reported a cumulative incidence of acute graft versus host disease at 100 days of 36% and a probability of survival of 78% at 100 days and 66% at both 1 and 3 years . The collaborative efforts of the transplant community have resulted in a decline of the risks associated with transplant across MPS [79, 80]; however, mortality rates still vary between centres, and serious risks, including death, remain. It is the opinion of the expert SC that risks may be higher in less experienced centres and it is therefore critical that HSCT is only performed in centres dedicated to transplant with access to an MDT with experience of managing patients with MPS. Matched donors should preferably not be carriers for MPS VI, and unrelated donors should be well-matched.
Overall, the expert consensus was that the risk–benefit profile of HSCT in patients with MPS VI is less clear than in other types of MPS, and further research, specifically, a well-designed comparative study of HSCT and ERT in patients of similar age and disease severity is needed to better understand the long-term efficacy and safety of HSCT in patients with MPS VI.
Considerations for monitoring response It is important to consider the life-long impact of HSCT on an individual basis, as the benefits of treatment manifest differently between each patient. Assessments should be performed prior to, and at least annually, after HSCT to measure the impact of transplantation on disease progression. Assessments should include: endurance testing, cardio-respiratory function (owing to the significant cardiac symptoms in patients with MPS VI), and measurement of height and weight. Follow-up should also include assessment of orthopaedic, ophthalmic, ENT, neurological and endocrine function. Data should be collected and shared in a manner that can advance the understanding of the risks and benefits of HSCT.
Interventions to support respiratory and sleep disorders
Continuous positive airway pressure (CPAP), non-invasive positive pressure ventilation (NIPPV), oxygen supplementation and hypercapnia monitoring (Table 6)
Rationale and evidence base Upper airway obstruction leading to obstructive sleep apnoea  is a common morbidity in patients with MPS VI and can significantly affect functional status and QoL [14, 82]. Typical features of MPS VI include upper and lower airway obstruction and restrictive pulmonary disease that occur from a variety of anatomic and functional abnormalities . Upper airway obstruction is attributable to cranial abnormalities, a short neck and progressive deposition of GAGs in the tissues surrounding the supraglottic upper respiratory tract, while lower airway obstruction reflects GAG deposition in the airway walls with resultant tracheal and bronchomalacia. Lung volume and chest expansion are further limited by short stature, chest wall deformities and abdominal organomegaly .
A comprehensive review of the evaluation and treatment options for sleep disordered breathing (SDB) in MPS has been recently published . Continuous positive airway pressure (CPAP) prevents upper airway collapse during inspiration and is the mainstay of treatment for OSA in the general population with beneficial effects on blood pressure, cardiac events, mortality and QoL . Recent studies have demonstrated effectiveness of CPAP in patients with MPS, showing improvement in pulmonary hypertension and cardio-respiratory failure [87,88,89]. An alternate form of therapy is required for patients who demonstrate either persistent OSA despite CPAP or hypoventilation during sleep. Non-invasive positive pressure ventilation (NIPPV) provides an increased pressure during the inspiratory phase of breathing to augment ventilation.
Supplemental oxygen can be prescribed for individuals that demonstrate persistent nocturnal oxygen desaturation and for patients who do not tolerate therapy with CPAP or NIPPV. Caution is required when prescribing oxygen because of the known complication of suppressing respiratory drive and arousal from sleep with potential for either worsening a pre-existing hypercapnia or inducing onset of hypercapnia is susceptible patients.
Considerations for management SDB can be managed by application of CPAP which delivers air at an elevated pressure via a mask that fits around the nose and/or mouth; however, consideration should be given to facial abnormalities that can make mask fitting difficult. Patients should be monitored to ensure they do not develop sustained hypoventilation. Vaccinations against respiratory pathogens causing influenza and pneumococcus infections are recommended.
Anaesthetics and surgical interventions
Use of anaesthesia in patients with MPS VI (Table 7)
Rationale and evidence base Patients with MPS VI will likely require anaesthesia for multiple surgical interventions and investigations to manage their disease [90, 91], but are considered high-risk for anaesthesia due to potential airway difficulties with mask ventilation and/or endotracheal intubation. Other risk factors include the presence of narrow airways due to adenotonsillar hypertrophy, macroglossia and deformity of the lower airway, skeletal abnormalities, pulmonary disposition and cardiac and neurological impairment [14, 92, 93]. Intubation and extubation can be challenging due to restricted mouth opening, short neck length with a limited range of motion, airway abnormalities already mentioned, micrognathia, subglottic narrowing, and atlanto-axial instability due to odontoid hypoplasia and ligamentous laxity [94,95,96]. Although hypothetical, poor perfusion related to arterial narrowing and reduced foramina diameters secondary to dysostosis should be anticipated by an anaesthetist, be appropriately monitored with arterial lines, and supported in the near-normal range during procedures.
Adverse events (including fatalities and paralysis) occurring during anaesthesia of patients with MPS have been reported in the literature . Although data on peripheral nerve blocks are lacking, this approach may be considered, and use of ultrasound technology can assist successful performance of these procedures and may allow avoidance of general anaesthesia in selected patients. Perioperative neurophysiological monitoring is recommended to prevent significant complications in this high-risk population; however, availability worldwide is extremely variable.
Considerations for anaesthesia Due to the risk of upper airway obstruction, pre-operative sedative premedication should be used with caution in patients with MPS VI and only with appropriate monitoring. Assessment of the upper and lower airways anatomy (for example, a pre-operative flexible nasopharyngolaryngoscopy and three-dimensional computerised tomography (CT) scan of the trachea, where feasible), cardiac function (including an ECG and echocardiogram), and potential cervical spine instability and compression, should be performed and function as baseline evaluation prior to any procedure that requires sedation or anaesthesia. This needs to be repeated at a future date with increase in age and weight. Similarly, MRI scans of the spine in a neutral position or a flexion/extension X-ray of the spine can be performed to assess the risk of spinal cord compression and instability (flexion/extension X-ray measures instability only). Flexion/extension imaging of the cervical spine prior to anaesthesia is required to assess atlantoaxial instability. The frequency of imaging should be dependent on both the patient’s age and clinical condition. To avoid spinal cord injury, sensory injury with dysesthetic pain, and/or loss of proprioception, it is critical to maintain a neutral neck position during all surgeries, including intubation and extubation. The aim is to avoid spinal cord injury which can lead to paralysis. When possible, intubation should be completed while patients are breathing spontaneously, and the use of paralytic agents should be avoided such that spontaneous breathing is maintained until intubation is completed successfully. Use of a smaller endotracheal tube size is usually necessary and often critical, to avoid intraoperative swelling of the airway and enable successful extubation. Where possible, patients should be extubated in the operating room (OR) and asked to demonstrate movement of all extremities. If safe intubation cannot be achieved, tracheostomy may be considered electively prior to prolonged surgery, or to facilitate post-operative care. If the patient is awake or breathing spontaneously, the option of delaying the surgery after failed intubation should be considered. Mean arterial pressure should be maintained to maximise perfusion of the spinal cord and reduce the risk of spinal cord injury. Displacing the tongue anteriorly prior to intubation by manual retraction using a ring forceps or a piece of gauze may help to access the larynx in children with MPS VI . Intensive care management is often not required but may be necessary for complicated or prolonged procedures requiring post-operative ventilation or peri-operative tracheostomy. If ventilated via an endotracheal tube, it is best to aim for early extubation to minimise swelling of the airway. When clinically indicated, maintenance of intubation overnight following the procedure may be considered to allow resolution of any airway swelling. Extubation should be performed by an experienced anaesthetist who can assess the airway before extubation and if necessary reintubate in the intensive care unit (ICU) or OR. Wherever possible, alternative techniques (e.g. peripheral nerve block under light sedation) should be considered to avoid general anaesthesia and the associated risks thereof. However, the surgical team should always be prepared to perform general anaesthesia when required.
Considerations after surgery Intraoperative use of steroids to reduce airway oedema is standard and the use of post-operative treatment may also be necessary for 24 h. Standard treatment for patients with upper airway obstruction should be available, including NIPPV, CPAP, and continuous monitoring of respiratory and cardiac function. ICU stays are not mandatory for all patients after all surgeries and should only be used when needed; nonetheless, availability of ICU facilities for management of complications, is critical. Intensive monitoring is required for 24–48 h post-surgery because of the potential complications of oral secretions, thoracic cage stiffness and heart and lung failure, which can include apnoea, laryngospasm, bronchospasm, cyanosis and respiratory failure.
Limb surgeries in patients with MPS VI (Table 8)
Rationale and evidence base MPS VI is characterised by profound skeletal dysplasia with cervical spinal canal stenosis, hip abnormalities and genu valgum . Hip problems can lead to severe disability . Patients with MPS VI have progressive musculoskeletal involvement, and numerous orthopaedic interventions are usually required to prevent deformity, improve function and reduce pain. Evidence from a prospective follow-up study showed that clinically significant hip abnormalities develop in all patients with MPS VI from very early on in life, starting with deformities of the os ilium and acetabulum. Femoral head abnormalities occur later and are most likely due to altered mechanical forces in combination with epiphyseal abnormalities due to GAG storage, however, the final shape and neck shaft angle differs significantly between individual patients and is difficult to predict . Case studies based on two patients with MPS I with skeletal dysplasia and thoracic kyphosis showed a rare complication of the spinal cord injury. This reiterated the importance of careful pre-operative assessments, including MRI of the spine, to reduce the risk of spinal cord injury .
Guided growth techniques for correction of genu valgum are not widely reported in patients with MPS VI; however, the indications for this approach need reconsideration in the era of ERT. A recent report of guided growth surgery conducted in two children with MPS VI while receiving ERT suggest that that this may be a useful approach to correcting knee deformities .
Patient selection for intervention Most patients with MPS VI will have abnormal radiographic findings; therefore, hip surgery should only be considered in patients who are symptomatic, as determined by presence of hip pain resulting in much reduced mobility and endurance. Growth modulation surgery should be initiated as soon as the deformity is observed, or if the tibial-femoral angle is > 15 degrees. For optimal results, it should be performed early during the period of growth, due to the deceleration in growth that occurs as the skeleton matures , however expert clinical opinion varies regarding the ideal age to perform the surgery. The period following ERT commencement may also be a good time to perform growth modulation surgery. Before orthopaedic intervention, morbidity and mortality risks, pain level, optimal timing and patient preference should be considered on a case-by-case basis.
Currently there is no hand surgical intervention that can be recommended to improve the weakness of the grip but maintain vital flexibility for transfer and adequate ADL. External custom-made splints can be worn to help with certain tasks e.g. heavy lifting. Occupational therapists are vital to help with ADL including providing gadgets to perform necessary tasks. Patients with weak grip can learn to adapt to master necessary ADL.
Considerations for surgery All surgeries should be supervised by an anaesthetist with experience in treating MPS and/or complex airway management (refer to the anaesthetics recommendations). Limb surgeries should be performed by an orthopaedic surgeon with a basic understanding of MPS and of the clinical presentation, musculoskeletal abnormalities, and radiographic findings associated with this group of disorders. An overnight hospital stay is recommended following hip surgery to allow access to intensive care, should this be needed, although this may not be necessary for surgeries such as hemi-epiphysiodesis. Long-term, intensive physical therapy is recommended post-surgery to enhance recovery, and assessment should be performed regularly as patients may require repeated surgeries/interventions. The primary goal of limb surgery is not to improve or restore joint range of motion (ROM), but rather to reduce pain or improve mobility. Goniometer measurements performed by a physiotherapist/occupational therapist/rheumatologist may be useful but may not be available in all centres.
Spinal surgeries in patients with MPS VI (Table 9)
Rationale and evidence base Skeletal abnormalities are early and prominent features of MPS VI and are potentially debilitating and life-threatening [14, 53]. Medical therapies for the management of MPS have a limited effect on the development of skeletal deformities; therefore, early surgical intervention is important to manage disease progression [100, 101]. The frequency of spinal cord compression and the success of surgical intervention has been reported by a clinical surveillance programme . Routine neurological history, examination and appropriate imaging should be part of standard care to detect early compromise of the spine.
Patient selection for intervention Indications for surgery include cervical spine cord compression as determined by clinical symptoms (including weakness, numbness, paraesthesia, and gait difficultly) or radiographic and MRI findings (including plain radiographic findings suggestive of stenosis and instability and MRI findings of extradural stenosis, cord compression, myelomalacia and instability). Physicians should consider the timing of such surgery in line with the need for cardiac valve replacement, as the latter procedure could subsequently commit the patient to lifetime anticoagulation therapy.
Considerations for surgery Spinal surgeries should be performed by a neurosurgeon and/or spinal surgeon with a basic understanding of MPS and of the clinical presentation, musculoskeletal abnormalities, and radiographic findings associated with this group of disorders.
Ophthalmic surgery in patients with MPS VI (Table 10)
Rationale and evidence base Corneal opacification leading to reduced visual acuity is a common feature in patients with MPS VI and does not appear to be influenced by ERT. Other ophthalmic findings in patients with MPS VI include high hyperopia, increased corneal thickness, optic nerve abnormalities, ocular hypertension, glaucoma, and rarely, retinopathy [103, 104]. Clear corneal grafts can be achieved for patients with MPS VI who have corneal clouding, and may result in improvements in visual acuity . Rejection episodes have been reported following corneal transplantation in patients with MPS VI; however, it should be noted that most occurred in those who were transplanted at a younger age (13–28 years old) [105, 106]. Generally, the recurrence of corneal deposits has not been reported in patients with MPS VI [105, 106].
Patient selection for intervention Corneal transplantation can be considered if corneal clouding is of such severity that it causes significant loss of vision and impacts QoL. The decision to perform corneal transplantation should be made on a case-by-case basis and should only be considered once retinopathy and optic nerve abnormalities have been assessed using electrodiagnostic (including electroretinography and visual evoked potentials) and have been excluded as a significant contributing factor to the loss of vision. The choice of surgical technique for corneal transplantation (deep anterior lamellar keratoplasty [DALK] or penetrating keratoplasty [PK]) should be made on a case-by-case basis. There is some evidence from the general population to suggest that rejection is more likely to occur following PK than DALK [106,107,108]; as such, DALK should be considered as the first approach in patients with MPS VI.
Considerations for intervention (e.g. if surgery) Monitored anaesthesia care with appropriate sedation and support with nasal CPAP/NIPPV may be used when performing eye surgery in patients with MPS VI. Signs of rejection require prompt ophthalmic assessment to prevent graft failure. Following corneal transplantation, long-term topical treatment is needed, as is regular (annual) ophthalmic assessment to determine the health of the corneal graft, assess for recurrence of corneal deposits and astigmatism control. Follow-up is also required to monitor for optic neuropathy due to raised intracranial pressure. This can be indicated by a reduction in visual acuity, new onset of visual field defect, abnormal pupil reactions, new onset of optic nerve swelling or (more commonly) optic atrophy and visual evoked potential abnormality.
Carpal tunnel decompression in patients with MPS VI (Table 11)
Rationale and evidence base Carpal tunnel syndrome (CTS) is a common condition in patients with MPS VI, which if left untreated, can lead to loss of nerve function. Trigger finger can also present in association with CTS in patients with MPS VI. Surgical decompression of CTS, especially when performed early, has reduced signs and symptoms of compressive myelopathy and improves the chance of preserving hand function [109, 110]. Evidence, albeit from limited case studies in patients with MPS, suggests that clinical improvements in hand/motor function, dexterity and spontaneous hand function are observed after carpal tunnel decompression (CTD), which are coupled with reduction in long-term hand pain and cessation of night pain . The preservation of hand function requires a combination of steps including decompression of the median nerve, tenosynovectomy and if necessary, an A1 and A3 pulley release rather than decompression alone. There are no data to suggest that an approach using tenosynovectomy alone is beneficial compared with tenosynovectomy plus complete epineurectomy; however, in rare cases, epineurotomy may be useful to achieve more effective decompression. Recurrence is frequent in older patients therefore repeated surgery may be indicated.
Patient selection for intervention CTD should be performed in patients who display restriction of hand function, including increased flexion contracture of the PIP and DIP joints, indicative of an increase in ‘scarred’ and tethered subsynovial connective tissue around the flexor tendons in the carpal canal. Clinical symptoms of hand pain/numbness include night pain, biting and/or slapping of fingers and pain or numbness in the thumb, index or middle finger. It is important to note that if a patient reports numbness in all fingers it is unlikely to be CTS, and pain in the little finger is suggestive of compression higher up than the carpal canal. Neurophysiological tests should be performed to rule out cervical compression before initiating surgery.
Considerations for surgery CTD should be performed by a hand surgeon with a basic understanding of MPS and of the clinical presentation associated with this group of disorders. In most cases, CTD may be performed with regional block plus sedation, with or without the use of LMA.
Considerations for post-surgery monitoring Regular post-surgical physical therapy may facilitate maintenance of increased hand movement. All patients who undergo CTD surgery should be assessed (pre- and post-surgery) for QoL, improvement in ROM and self-reported change in function.
Cardio-thoracic surgery in patients with MPS VI (Table 12)
Rationale and evidence base Cardiac valve disease, which occurs as a result of valve thickening from deposition of storage material, occurs commonly in patients with MPS VI  and is a major cause of morbidity and mortality. Cardio-thoracic surgery in patients with MPS VI can be challenging because of small patient size and associated skeletal and pulmonary co-morbidities. Evidence from several case reports and small case series suggests that replacement of the aortic and mitral valves, either singly or in combination, is feasible in patients with MPS VI [112,113,114,115,116]. Successful resection of a left ventricular apical aneurysm, a rare complication of MPS VI, has been reported , but successful balloon dilation of aortic or mitral valves has not.
Patient selection for intervention (refer to the recommendations for routine assessments and monitoring) The performance and interpretation of findings of echocardiography should be completed by individuals familiar with the expected pathological findings in patients with MPS VI. Valve replacement decisions should be based on current European/American (AHA) guidelines [118, 119] in conjunction with assessment of existing co-morbidities, operative risk and rehabilitation potential. Trans-catheter aortic valve replacement may be appropriate for some patients with MPS VI. The Ross procedure is contraindicated in patients with systemic valvular disease. Small valve annulus may preclude valve replacement with currently existing mechanical and bio-prosthetic cardiac valves.
Consideration for surgery Cardiac surgery in patients with MPS VI should be performed in a centre of excellence with a team experienced in both managing patients with MPS and performing high-risk valve replacement surgery. When possible, an anaesthetic specialist with experience in managing patients with MPS should assist the cardiac anaesthetic team during pre-operative assessment in formulating an MPS-related anaesthesia care plan. Similarly, the anaesthetic care plan for cardiac catheterisation should be formulated jointly by the cardiologist and anaesthetic care team specialist. Airway care, including the need for tracheostomy, should be assessed on a case-by-case basis.
Ear, nose and throat surgery in patients with MPS VI (Table 13)
Rationale and evidence base ENT manifestations are common in patients with MPS VI and often involve hearing disorders, otitis media and upper airway obstruction . Permanent hearing loss is common and is believed to be conductive and neurosensory in nature [14, 120]. Results from two non-randomised studies revealed that ENT surgery reduced hypoacusia, otitis media, incidence of upper respiratory tract infections, occurrence of OSA and need for Type B tympanograms. QoL was also reported to be improved in some patients [82, 121]. The results from another non-randomised study suggest that tonsillectomy and/or adenoidectomy significantly improves post-operative sleep apnoea in MPS patients . Development of secondary haemorrhage is a serious risk associated with tonsillectomy and/or adenoidectomy in patients with MPS as difficult intubations are common in these patients and can be fatal [82, 122]. Evidence from a case series shows that insertion of ventilation tubes can improve air and bone conduction and the air-bone gap in patients with MPS VI . Advanced surgical options such as uvulopalatopharyngoplasty (UPPP), mandibular advancement surgery and tongue reduction are currently experimental. While one member of the SC had experience, currently, there is not enough evidence from which to derive any recommendations about the use of these invasive procedures in patients with MPS VI.
Considerations for surgery Vaccinations against respiratory pathogens causing influenza and pneumococcus infections are recommended to prevent pneumonia. Insertion of ventilation tubes should be performed according to the guidelines for the general paediatric population [123, 124]. Patients who have had tonsillectomy and/or adenotonsillectomy should be observed as in-patients and may need to remain in hospital preferably in intensive care in the early post-operative period to monitor airway patency. They may need to remain hospitalised for additional days to allow close monitoring for possible haemorrhage and other complications. Patients with ventilation tubes should be assessed every three months and if improvement in hearing is absent, a post-operative audiologic assessment should be performed. The anaesthesia plan should be discussed jointly between the otolaryngologist and anaesthesia care team and precautions should be taken to prevent spinal cord compression during surgical procedures. However, before performing tonsillectomy, children with MPS should be referred by the clinician for polysomnography for sleep .
Where evidence is scarce, systematic approaches are required to ensure the evidence-base is as extensive as possible. This programme involved a validated systematic approach to the development of guidance statements and the resulting publication therefore addresses this unmet need by creating a robust, holistic set of recommendations for healthcare professionals managing patients with MPS VI. A detailed discussion on the development of the guidance methodology, strengths and limitations of the programme, future directions, facilitators/barriers to support the application of the guidance including cost considerations, and conclusions is provided in the discussion of the companion article of this publication ( Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance ).
This manuscript provides robust evidence- and consensus-driven guidance for the management of patients with MPS VI. The guidance is intended for use by healthcare professionals that manage the holistic care of patients with MPS with the intention to enhance patient quality of life and improve clinical- and patient-reported outcomes. It recognised that the guidance provided represents a point in time and further research is required to address current knowledge/evidence gaps. The SC recommends that this guidance is reviewed and updated within 5 years, or sooner if there are significant changes to medical practice.
Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v4–12.
James RA, Singh-Grewal D, Lee SJ, McGill J, Adib N, Australian Paediatric Rheumatology G. Lysosomal storage disorders: a review of the musculoskeletal features. J Paediatr Child Health. 2016;52:262–71.
Leone A, Rigante D, Amato DZ, Casale R, Pedone L, Magarelli N, et al. Spinal involvement in mucopolysaccharidoses: a review. Childs Nerv Syst. 2015;31:203–12.
Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012;2012:471325.
Cimaz R, La Torre F. Mucopolysaccharidoses. Curr Rheumatol Rep. 2014;16:389.
Archer LD, Langford-Smith KJ, Bigger BW, Fildes JE. Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis. 2014;37:1–12.
Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011–7.
Malm G, Lund AM, Mansson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008;97:1577–81.
Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5.
Silipo A, Zhang Z, Canada FJ, Molinaro A, Linhardt RJ, Jimenez-Barbero J. Conformational analysis of a dermatan sulfate-derived tetrasaccharide by NMR, molecular modeling, and residual dipolar couplings. Chembiochem. 2008;9:240–52.
Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Investig. 2001;81:1319–28.
Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res. 2005;57:701–7.
Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A. 2005;134A:144–50.
Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007;120:405–18.
Wood TC, Harvey K, Beck M, Burin MG, Chien YH, Church HJ, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013;36:293–307.
Jurecka A, Golda A, Opoka-Winiarska V, Piotrowska E, Tylki-Szymanska A. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) with a predominantly cardiac phenotype. Mol Genet Metab. 2011;104:695–9.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32:1008–15.
Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401–9.
Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182:E839–42.
Politei JM, Gordillo-Gonzalez G, Guelbert N, Souza CFM, Lourenco CM, Solano ML, et al. Recommendations for evaluation and management of pain in patients with mucopolysaccharidosis in Latin America. J Pain Symptom Manage. 2018;56(1):146–52.
Congedi S, Di Pede C, Scarpa M, Rampazzo A, Benini F. The complexity of pain Management in Children Affected by Mucopolysaccharidoses. Case Rep Pediatr. 2017;2017:7257230.
Oussoren E, Bessems J, Pollet V, van der Meijden JC, van der Giessen LJ, Plug I, et al. A long term follow-up study of the development of hip disease in Mucopolysaccharidosis type VI. Mol Genet Metab. 2017;121:241–51.
Garcia P, Sousa SB, Ling TP, Conceicao M, Seabra J, White KK, et al. Skeletal complications in mucopolysaccharidosis VI patients: case reports. J Pediatr Rehabil Med. 2010;3:63–9.
Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681–9.
Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.
Kubaski F, Suzuki Y, Orii K, Giugliani R, Church HJ, Mason RW, et al. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses. Mol Genet Metab. 2017;120:247–54.
Langereis EJ, Wagemans T, Kulik W, Lefeber DJ, van Lenthe H, Oussoren E, et al. A multiplex assay for the diagnosis of mucopolysaccharidoses and mucolipidoses. PLoS One. 2015;10:e0138622.
Zhang H, Wood T, Young SP, Millington DS. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses. Mol Genet Metab. 2015;114:123–8.
Zhang H, Young SP, Millington DS. Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. Curr Protoc Hum Genet. 2013;Chapter 17:Unit 17 2.
Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2014;9:135.
Saville JT, McDermott BK, Fletcher JM, Fuller M. Disease and subtype specific signatures enable precise diagnosis of the mucopolysaccharidoses. Genet Med. 2019;21(3):753–57.
Lin SM, Lin HY, Chuang CK, Lin SP, Chen MR. Cardiovascular abnormalities in Taiwanese patients with mucopolysaccharidosis. Mol Genet Metab. 2014;111:493–8.
Chen MR, Lin SP, Hwang HK, Yu CH. Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol. 2005;60:51–3.
Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183–97.
Horovitz DD, Magalhaes Tde S, Pena e Costa A, Carelli LE, Souza e Silva D, de Linhares e Riello AP, et al. Spinal cord compression in young children with type VI mucopolysaccharidosis. Mol Genet Metab. 2011;104:295–300.
Kasapkara CS, Tumer L, Aslan AT, Hasanoglu A, Ezgu FS, Kucukcongar A, et al. Home sleep study characteristics in patients with mucopolysaccharidosis. Sleep Breath. 2014;18:143–9.
Lin HY, Chen MR, Lin CC, Chen CP, Lin DS, Chuang CK, et al. Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol. 2010;45:1205–12.
Lin HY, Shih SC, Chuang CK, Lee KS, Chen MR, Lin HC, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol Genet Metab. 2014;111:533–8.
Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB. Drugs R D. 2005;6:312–5.
Giugliani R, Lampe C, Guffon N, Ketteridge D, Leao-Teles E, Wraith JE, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A. 2014;164A:1953–64.
Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) clinical surveillance program (CSP). J Inherit Metab Dis. 2013;36:373–84.
Decker C, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010;3:89–100.
Harmatz P, Hendriksz CJ, Lampe C, McGill JJ, Parini R, Leao-Teles E, et al. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Mol Genet Metab. 2017;122:107–12.
Brunelli MJ, Atallah AN, da Silva EM. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. Cochrane Database Syst Rev. 2016;3:CD009806.
Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94:469–75.
Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533–9.
McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, Swiedler SJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet. 2010;77:492–8.
But WM, Wong MY, Chow JC, Chan WK, Ko WT, Wu SP, et al. Enzyme replacement therapy for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): experience in Hong Kong. Hong Kong Med J. 2011;17:317–24.
Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(R)) therapy. J Inherit Metab Dis. 2013;36:385–94.
Horovitz DD, Magalhaes TS, Acosta A, Ribeiro EM, Giuliani LR, Palhares DB, et al. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab. 2013;109:62–9.
Brands MM, Hoogeveen-Westerveld M, Kroos MA, Nobel W, Ruijter GJ, Ozkan L, et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet J Rare Dis. 2013;8:51.
Brands MM, Oussoren E, Ruijter GJ, Vollebregt AA, van den Hout HM, Joosten KF, et al. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol Genet Metab. 2013;109:70–6.
Harmatz PR, Garcia P, Guffon N, Randolph LM, Shediac R, Braunlin E, et al. Galsulfase (Naglazyme(R)) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis. 2014;37:277–87.
Jurecka A, Opoka-Winiarska V, Jurkiewicz E, Marucha J, Tylki-Szymanska A. Spinal cord compression in Maroteaux-Lamy syndrome: case report and review of the literature with effects of enzyme replacement therapy. Pediatr Neurosurg. 2012;48:191–8.
Horovitz DDG, Acosta AX, de Rosso Giuliani L, Ribeiro EM. Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: six years follow-up of four children. Mol Genet Metab Rep. 2015;5:19–25.
Naglazyme Summary of Product Characteristics (EU). 2005. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000640/WC500024289.pdf. Accessed 16 July 2018.
Naglazyme prescribing information (US). 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/125117_0000_lbl.pdf. Accessed 16 Aug 2018.
Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-year follow up. Mol Genet Metab Rep. 2017;13:69–75.
Franco JF, Soares DC, Torres LC, Leal GN, Cunha MT, Honjo RS, et al. Short communication impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings. Genet Mol Res. 2016;15(1).
Leal GN, de Paula AC, Morhy SS, Andrade JL, Kim CA. Advantages of early replacement therapy for mucopolysaccharidosis type VI: echocardiographic follow-up of siblings. Cardiol Young. 2014;24:229–35.
Hendriksz CJ, Harmatz P, Giugliani R, Roberts J, Arul GS. Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders. Mol Genet Metab Rep. 2018;15:71–3.
McLoughlin M, Stepien KM, McNelly B, Thompson L, Gorton J, Hendriksz CJ. The use of port-a-caths in adult patients with lysosomal storage disorders receiving enzyme replacement therapy-one Centre experience. Mol Genet Metab Rep. 2017;13:111–4.
Harmatz P, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2010;33:51–60.
Boelens JJ, Wynn RF, O'Meara A, Veys P, Bertrand Y, Souillet G, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225–33.
Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R, et al. Outcomes of transplantation using various hematopoietic cell sources in children with hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981–7.
Ghosh A, Miller W, Orchard PJ, Jones SA, Mercer J, Church HJ, et al. Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis type I: 10 year combined experience of 2 centres. Mol Genet Metab. 2016;117:373–7.
Patel P, Suzuki Y, Tanaka A, Yabe H, Kato S, Shimada T, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with hunter syndrome. Mol Genet Metab Rep. 2014;1:184–96.
Coman DJ, Hayes IM, Collins V, Sahhar M, Wraith JE, Delatycki MB. Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians. JIMD Rep. 2011;1:9–15.
Parini R, Rigoldi M, Tedesco L, Boffi L, Brambilla A, Bertoletti S, et al. Enzymatic replacement therapy for hunter disease: up to 9 years experience with 17 patients. Mol Genet Metab Rep. 2015;3:65–74.
Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for hurler syndrome: an international multicenter comparison. Genet Med. 2018;20(11):1423–29.
Herskhovitz E, Young E, Rainer J, Hall CM, Lidchi V, Chong K, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis. 1999;22:50–62.
Papsin BC, Vellodi A, Bailey CM, Ratcliffe PC, Leighton SE. Otologic and laryngologic manifestations of mucopolysaccharidoses after bone marrow transplantation. Otolaryngol Head Neck Surg. 1998;118:30–6.
Golda A, Jurecka A, Opoka-Winiarska V, Tylki-Szymanska A. Mucopolysaccharidosis type VI: a cardiologist's guide to diagnosis and treatment. Int J Cardiol. 2013;167:1–10.
Jester S, Larsson J, Eklund EA, Papadopoulou D, Mansson JE, Bekassy AN, et al. Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome. Orphanet J Rare Dis. 2013;8:134.
Turbeville S, Nicely H, Rizzo JD, Pedersen TL, Orchard PJ, Horwitz ME, et al. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab. 2011;102:111–5.
Summers CG, Purple RL, Krivit W, Pineda R 2nd, Copland GT, Ramsay NK, et al. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation. A preliminary report. Ophthalmology. 1989;96:977–84 discussion 84-5.
Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology. 1998;105:1099–105.
Aldenhoven M, Jones S, Bonney D, Borrill R, Coussons M, Mercer J, et al. Hematopoietic cell transplantation for MPS patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21:S93.
Boelens JJ, Orchard PJ, Wynn RF. Transplantation in inborn errors of metabolism: current considerations and future perspectives. Br J Haematol. 2014;167:293–303.
Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130:576–84.
Gonuldas B, Yilmaz T, Sivri HS, Gucer KS, Kilinc K, Genc GA, et al. Mucopolysaccharidosis: Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway. Int J Pediatr Otorhinolaryngol. 2014;78:944–9.
Muhlebach MS, Wooten W, Muenzer J. Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev. 2011;12:133–8.
Berger KI, Fagondes SC, Giugliani R, Hardy KA, Lee KS, McArdle C, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36:201–10.
Rapoport DM, Mitchell JJ. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses. Mol Genet Metab. 2017;122S:49–54.
Piper AJ, Yee BJ. Hypoventilation syndromes. Compr Physiol. 2014;4:1639–76.
Ginzburg AS, Onal E, Aronson RM, Schild JA, Mafee MF, Lopata M. Successful use of nasal-CPAP for obstructive sleep apnea in hunter syndrome with diffuse airway involvement. Chest. 1990;97:1496–8.
Orliaguet O, Pepin JL, Veale D, Kelkel E, Pinel N, Levy P. Hunter's syndrome and associated sleep apnoea cured by CPAP and surgery. Eur Respir J. 1999;13:1195–7.
Chan D, Li AM, Yam MC, Li CK, Fok TF. Hurler's syndrome with cor pulmonale secondary to obstructive sleep apnoea treated by continuous positive airway pressure. J Paediatr Child Health. 2003;39:558–9.
Walker R, Belani KG, Braunlin EA, Bruce IA, Hack H, Harmatz PR, et al. Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36:211–9.
Moores C, Rogers JG, McKenzie IM, Brown TC. Anaesthesia for children with mucopolysaccharidoses. Anaesth Intensive Care. 1996;24:459–63.
Walker RW, Darowski M, Morris P, Wraith JE. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia. 1994;49:1078–84.
Frawley G, Fuenzalida D, Donath S, Yaplito-Lee J, Peters H. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses. Paediatr Anaesth. 2012;22:737–44.
Theroux MC, Nerker T, Ditro C, Mackenzie WG. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth. 2012;22:901–7.
Walker RW, Colovic V, Robinson DN, Dearlove OR. Postobstructive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. Paediatr Anaesth. 2003;13:441–7.
Walker RW, Allen DL, Rothera MR. A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway. Paediatr Anaesth. 1997;7:421–6.
Herrick IA, Rhine EJ. The mucopolysaccharidoses and anaesthesia: a report of clinical experience. Can J Anaesth. 1988;35:67–73.
Wood M, JE D AM, DM E. Guided growth surgery for genu valgum in mucopolysaccharidosis type VI. Mol Genet Metab. 2017;120:S141.
Pruszczynski B, Mackenzie WG, Rogers K, White KK. Spinal cord injury after extremity surgery in children with thoracic kyphosis. Clin Orthop Relat Res. 2015;473:3315–20.
White KK, Jester A, Bache CE, Harmatz PR, Shediac R, Thacker MM, et al. Orthopedic management of the extremities in patients with Morquio a syndrome. J Child Orthop. 2014;8:295–304.
Dalvie SS, Noordeen MH, Vellodi A. Anterior instrumented fusion for thoracolumbar kyphosis in mucopolysaccharidosis. Spine (Phila Pa 1976). 2001;26:E539–41.
Solanki GA, Sun PP, Martin KW, Hendriksz CJ, Lampe C, Guffon N, et al. Cervical cord compression in mucopolysaccharidosis VI (MPS VI): findings from the MPS VI clinical surveillance program (CSP). Mol Genet Metab. 2016;118:310–8.
Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51:1–17.
Leung LSWG, Hobson RR. Further electroretinographic studies of patients with mucopolysaccharidoses. Birth Defects Orig Artic Ser. 1971;7:32–40.
Bothun ED, Decanini A, Summers CG, Orchard PJ, Tolar J. Outcome of penetrating keratoplasty for mucopolysaccharidoses. Arch Ophthalmol. 2011;129:138–44.
Ohden KL, Pitz S, Ashworth J, Magalhaes A, Marinho DR, Lindahl P, et al. Outcomes of keratoplasty in the mucopolysaccharidoses: an international perspective. Br J Ophthalmol. 2017;101:909–12.
Keane M, Coster D, Ziaei M, Williams K. Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus. Cochrane Database Syst Rev. 2014;(7):CD009700.
Fenzl CR, Teramoto K, Moshirfar M. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol. 2015;9:1633–44.
Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg Am. 1998;23:236–43.
Yuen A, Dowling G, Johnstone B, Kornberg A, Coombs C. Carpal tunnel syndrome in children with mucopolysaccaridoses. J Child Neurol. 2007;22:260–3.
Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jungst BK. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr. 1995;154:98–101.
Tan CT, Schaff HV, Miller FA Jr, Edwards WD, Karnes PS. Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation. 1992;85:188–95.
Hachida M, Nonoyama M, Bonkohara Y, Hanayama N, Koyanagi H. Combined aortic and mitral valve replacement in an adult with mucopolysaccharidosis (Maroteaux-Lamy syndrome). Heart Vessel. 1996;11:215–7.
Marwick TH, Bastian B, Hughes CF, Bailey BP. Mitral stenosis in the Maroteaux-Lamy syndrome: a treatable cause of dyspnoea. Postgrad Med J. 1992;68:287–8.
Thumler A, Miebach E, Lampe C, Pitz S, Kamin W, Kampmann C, et al. Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. J Inherit Metab Dis. 2012;35:1071–9.
Torre S, Scarpelli M, Salviati A, Buffone E, Faggian G, Luciani GB. Aortic and mitral valve involvement in Maroteaux-Lamy syndrome VI: surgical implications in the enzyme replacement therapy era. Ann Thorac Surg. 2016;102:e23–5.
Oudit GY, Butany J, Williams WG, Siu SC, Clarke JT, Iwanochko RM. Left ventricular aneurysm in a patient with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): clinical and pathological correlation. Cardiovasc Pathol. 2007;16:237–40.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.
Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2005;69:589–95.
Mesolella M, Cimmino M, Cantone E, Marino A, Cozzolino M, Della Casa R, et al. Management of otolaryngological manifestations in mucopolysaccharidoses: our experience. Acta Otorhinolaryngol Ital. 2013;33:267–72.
Sudarsan SS, Paramasivan VK, Arumugam SV, Murali S, Kameswaran M. Comparison of treatment modalities in syndromic children with obstructive sleep apnea--a randomized cohort study. Int J Pediatr Otorhinolaryngol. 2014;78:1526–33.
Apfelbaum JL, Hagberg CA, Caplan RA, Blitt CD, Connis RT, Nickinovich DG, et al. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Anesthesiology. 2013;118:251–70.
Society DA. DAS Paediatric Difficult Airway Guidelines. 2015. https://www.das.uk.com/guidelines/downloads.html. Accessed 28 June 2018.
Roland PS, Rosenfeld RM, Brooks LJ, Friedman NR, Jones J, Kim TW, et al. Clinical practice guideline: polysomnography for sleep-disordered breathing prior to tonsillectomy in children. Otolaryngol Head Neck Surg. 2011;145:S1–15.
The authors would like to remember and dedicate this paper to their colleague and fellow SC member, Christine Lavery, MBE, Chief Executive of the Society for Mucopolysaccharide Diseases (MPS Society) and fearless advocate for those with MPS, who sadly passed away before completion of this programme. The authors would like to thank Dr. Francyne Kubaski, BS, MSc, PhD, of HCPA and UFRGS, Porto Alegre, Brazil and Dr. Gregory Lamb and Dr. Kealeboga Rammego, of Steve Biko Academic Unit, University of Pretoria, South Africa for their role as Bibliographic Fellows and assistance with literature searches and analysis; Michele Hilton Boon, Angela Perez Gomez and Karen Spithoff for reviewing the manuscript against the AGREE II Instrument; the PAG groups: Casa Hunter, German MPS Society, National MPS Society, The Isaac Foundation, Turkish MPS Society and UK MPS Society for their consultations which informed the guidance development. Programme support was provided by Rebecca Bellerby PhD, James Hadfield, BA (Oxon) and Hannah Tivey PhD of Lucid Partners Ltd., Burleighfield House, Buckinghamshire, United Kingdom. Medical writing and editorial support to the authors in the development of this manuscript was provided by Lucid Partners Ltd., Burleighfield House, Buckinghamshire, United Kingdom; financial support for these services was provided by BioMarin.
MPS Consensus Programme Steering Committee:
Mehmet Umut Akyol, Tord D. Alden, Hernan Amartino, Jane Ashworth, Kumar Belani, Kenneth I. Berger, Andrea Borgo, Elizabeth Braunlin, Yoshikatsu Eto, Jeffrey I. Gold, Andrea Jester, Simon A. Jones, Cengiz Karsli, William Mackenzie, Diane Ruschel Marinho, Andrew McFadyen, Jim McGill, John J. Mitchell, Joseph Muenzer, Torayuki Okuyama, Paul J. Orchard, Bob Stevens, Sophie Thomas, Robert Walker, Robert Wynn.
MPS Consensus Programme Co-Chairs:
Roberto Giugliani, Paul Harmatz, Christian Hendriksz, Maurizio Scarpa.
The programme was funded by BioMarin; however, they remained uninvolved throughout the whole process and did not influence the scope or content of the programme. The funder was absent from all SC meetings, remained blinded to the guidance statements and were not involved in the publication process. The SC was identified through a systematic expert mapping process, conducted independently of the funder.
Availability of data and materials
All data generated or analysed during this study are included in this published article and its supplementary information files.
Ethics approval and consent to participate
Consent for publication
P Harmatz has conducted consultancy work and/or has received grant support from Alexion, Armagen, BioMarin Pharmaceutical Inc., Chiesi, Denali, Genzyme, Enzyvant, Inventiva, JCR Pharmaceuticals, Orphazyme, Pfizer, PTC Therapeutics, RegenXbio, Sangamo, Shire, SOBI and Ultragenyx. C Hendriksz; is Owner and Director of FYMCA Medical Ltd.; has conducted consultancy work for Actelion, Amicus, Alexion, Audentes, BioMarin Pharmaceutical Inc., Chiesi, Evidera, Inventiva, GSK, SOBI, Health Care at Home, Sanofi Genzyme, Shire. R Giugliani has received consultancy fees, and/or investigator fees, and/or speaker honoraria and/or travel grants to attend scientific meetings from Actelion, Amicus, Armagen, BioMarin, Chiesi, GC Pharma, Inventiva, JCR Pharmaceuticals, Lysogene, RegenxBio, Sanofi Genzyme, Shire, Sobi, and Ultragenyx. M Scarpa has received honoraria, research and travel grants from Alexion, BioMarin Pharmaceutical Inc., Chiesi, Sanofi Genzyme, Shire, Ultragenix and Sangamo. MU Akyol has received speaker honoraria and travel grants from Shire. J Ashworth has received honoraria, travel expenses and a research grant from BioMarin Pharmaceutical Inc. and has received consultancy fees from AbbVie and Inventiva. T Alden has received consultant and honoraria payments from BioMarin Pharmaceutical Inc. and Shire. K Belani was a co-investigator on several studies funded by grants from Lysogene and Shire and has received a travel grant from BioMarin Pharmaceutical Inc. for attendance at an advisory meeting. H Amartino has conducted investigator, speaker and consultant work for Amicus, BioMarin Pharmaceutical Inc., Bluebird Bio, Sanofi Genzyme and Shire. K Berger has received consultancy and honoraria payments from BioMarin Pharmaceutical Inc. and Sanofi Genzyme. A Borgo has received travel grants and honoraria from BioMarin Pharmaceutical Inc., and honoraria from Brains for Brains and Shire. E Braunlin has received speaker and travel grants from BioMarin Pharmaceutical Inc. and Sanofi Genzyme, a research funding from BioMarin Pharmaceutical Inc. and Bluebird Bio and has conducted consultancy work for Ultragenyx. Y Eto has received research grants and honoraria from BioMarin Pharmaceutical Inc., Alexion Pharmaceutical Inc., Sanofi Genzym and Actelion Pharmaceuticals Ltd., and honoraria from Dainippon Sumitomo Inc., Japan Chemical Research and Shire Japan. JI Gold has received honoraria and travel grants from BioMarin Pharmaceutical Inc. A Jester has received honoraria, travel grants, and research funding from BioMarin Pharmaceutical Inc. and funding from Shire for equipment to conduct outcomes assessment. S Jones has conducted investigator, speaker and consultancy work for Alexion, BioMarin Pharmaceutical Inc., Orchard therapeutics, Sanofi Genzyme, Shire and Ultragenyx. C Karsli has nothing to disclose. W MacKenzie has received travel grants and honoraria from BioMarin Pharmaceutical Inc. and has conducted consultancy work for Johnson & Johnson. A McFadyen has received unrestricted educational grants from Alexion, BioMarin Pharmaceutical Inc., Sanofi Genzyme, Shire, and Johnson and Johnson. J McGill has conducted speaker, consultancy, board member work and received travel grants from Actelion, BioMarin Pharmaceutical Inc., Sanofi Genzyme and Shire. He has been an investigator for BioMarin Pharmaceutical Inc. J Mitchell has received research support, advisory board fees, and travel grants from BioMarin Pharmaceutical Inc. and has been involved in the conduct of BioMarin clinical trials. He has also received research funding from Sanofi Genzyme and Shire. He has received consultancy fees from Ultragenyx, BioMarin Pharmaceutical Inc., Sanofi Genzyme and Shire. J Muenzer has conducted consultancy work and/or has received grant support from BioMarin Pharmaceutical Inc., Denali, Green Cross, Eloxx, PTC Therapeutics, RegenXbio, Sangamo, Sanofi Genzyme, Shire and Sobi. T Okuyama has received research grant from BioMarin Pharmaceutical Inc., Green Cross, Sanofi Genzyme, Shire, Orchard Therapeutics, and JCR, and has attended advisory boards for Sanofi Genzyme. He is Principal Investigator for ERT clinical trials for MPS II sponsored by Green Cross and JCR. P Orchard has received honoraria, travel and research support from Sanofi Genzyme, and has received research support from BioMarin Pharmaceutical Inc., Bluebird Bio and Horizon Pharma. B Stevens has received grants for the MPS Society from Sanofi Genzyme, Shire, Sangamo, Regenxbio, BioMarin Pharmaceuticals Inc. and Ultragenyx for direct advocacy, expert meetings, literature and travel. S Thomas has received grants for the MPS Society from Sanofi Genzyme, Shire, Sangamo, Regenxbio, BioMarin Pharmaceuticals Inc., Chiesi and Ultragenyx for direct advocacy, expert meetings, honoraria, literature and travel. DR Marinho has received honoraria and travel grants from BioMarin Pharmaceutical Inc. R Walker has received travel grants, honorarium and payments for consulting work from BioMarin Pharmaceutical Inc., Sanofi Genzyme and Shire. R Wynn has conducted consultancy work for Chimerix, Bluebird Bio and Orchard Therapeutics.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Methodology. Further information regarding methodology, including: defining clinical questions using the P.I.C.O methodology, the search strategy recording form, results of the systematic literature review according to PRISMA, the Oxford Centre for Evidence-based Medicine criteria and the AGREE II evaluation. (DOCX 69 kb)
Oxford CEBM grading for MPS IVA: Tables detailing the evidence levels given to each reference supporting the MPS IVA guidance statements and the Evidence Grades applied to each guidance statement. Evidence levels were assessed using the Oxford Centre for Evidence-based Medicine and were based on the quality of evidence of each reference. For each guidance statement, an overall Evidence Grade was applied, based on the evidence levels of the supporting references. (DOCX 41 kb)
Oxford CEBM grading for MPS VI. Tables detailing the evidence levels given to each reference supporting the MPS VI guidance statements and the Evidence Grades applied to each guidance statement. Evidence levels were assessed using the Oxford Centre for Evidence-based Medicine and were based on the quality of evidence of each reference. For each guidance statement, an overall Evidence Grade was applied, based on the evidence levels of the supporting references. (DOCX 41 kb)
Modified-Delphi voting Round 1. Full results of the first round of the modified-Delphi voting, which was used to demonstrate consensus of the guidance statements. (DOCX 151 kb)
Modified-Delphi voting Round 2. Full results of the second round of the modified-Delphi voting, which was used to demonstrate consensus of the guidance statements. (DOCX 41 kb)
About this article
Cite this article
Akyol, M.U., Alden, T.D., Amartino, H. et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis 14, 118 (2019). https://doi.org/10.1186/s13023-019-1080-y
- Maroteaux-Lamy syndrome
- MPS VI
- Management guidelines
- Enzyme replacement therapy
- Haematopoietic stem cell transplantation